The COVID-19 pandemic has had a significant impact on the biguanides market, with the prevalence of diabetes in COVID-19 hospitalized individuals emphasizing the role of oral anti-diabetic drugs.
The COVID-19 pandemic has had a profound impact on the biguanides market. With the prevalence of diabetes in COVID-19 hospitalized individuals, the role of oral anti-diabetic drugs, including biguanides, has become even more crucial. People with diabetes already have weakened immune systems, which makes them more susceptible to severe illness or death from COVID-19. Uncontrolled hyperglycemia further compounds the risk for these patients.
Biguanides, with metformin being the primary example, play a pivotal role in treating type 2 diabetes. They work to reduce glucose production during digestion, helping to control blood sugar levels. The COVID-19 pandemic has highlighted the importance of glucose control, as there is a clear association between type 2 diabetes and adverse clinical outcomes in COVID-19 patients. Metformin, with its proven efficacy, safety, and cost-effectiveness, is often the first-line pharmacotherapy for managing hyperglycemia in these patients.
Beyond its glucose-lowering role, metformin also exhibits significant anti-inflammatory properties. This makes it a potential candidate for treating individuals with both COVID-19 infection and type 2 diabetes during these challenging pandemic times. The anti-inflammatory properties of metformin may help mitigate the inflammatory response associated with severe COVID-19 cases.
The worldwide diabetes population is projected to grow by over 1.9% during the forecast period, driven by factors such as obesity and lifestyle changes. Metformin’s effectiveness, safety, and affordability contribute to its status as the most prescribed oral antidiabetic medication globally.
The Asia-Pacific region leads the biguanides market, accounting for approximately 37.9% of the market share. This region has witnessed a surge in diabetes prevalence, particularly in developing nations like China and India. Lifestyle changes, including unhealthy diets and sedentary lifestyles, contribute significantly to the rise in diabetes cases. Governments in these countries have implemented programs to combat non-communicable diseases like diabetes, which further fuels the demand for diabetes management, including the use of biguanides.
In conclusion, the COVID-19 pandemic has underscored the importance of biguanides, particularly metformin, in managing type 2 diabetes and its associated risks. With the global diabetes population projected to grow, the demand for biguanides is expected to continue to rise, especially in regions like the Asia-Pacific. The unique properties of metformin, such as its glucose-lowering and anti-inflammatory effects, make it a valuable option for individuals with both COVID-19 and type 2 diabetes.
